Speakers

Keynote Speaker - F.E. Shideman Distinguished Alumni Award Winner

"Overcoming Resistance to Molecularly Targeted Cancer Therapy"

Richard A. Heyman, Ph.D.

Executive Chairman and Co-Founder, Metacrine Inc.

2015 Department of Pharmacology F.E. Shideman Distinguished Alumni Award Recipient

Richard A. Heyman, Ph.D., currently serves as Executive Chairman and Co-Founder of Metacrine Inc., a biotech start up company, formed in June 2015 developing new therapeutics for the treatment of diabetes, fatty liver diseases and related metabolic disorders. Previously, he served as CEO of Seragon Pharmaceuticals; Seragon was a San Diego based biotech company that focused on the discovery and development of Selective Estrogen Receptor Degraders (SERDs) targeting ER+ breast cancers which was acquired by Genentech/Roche in August 2014.

Prior to Seragon, he co-founded and was CEO of Aragon Pharmaceuticals, which advanced next generation therapeutics for hormone dependent cancers based on new insights into molecular mechanisms of resistance. Johnson & Johnson purchased Aragon in August 2013 and simultaneous with this acquisition, Seragon Pharmaceuticals was spun out and created.

Earlier in his career, he co-founded and served as Chief Scientific Officer of X-Ceptor Therapeutics, a company that developed compounds targeting nuclear receptors for the treatment of metabolic diseases.

Following his post-doctoral training, he joined and held various roles at Ligand Pharmaceuticals, including Vice President of Research, where he served as project leader leading to the successful identification and development of Panretin® and Targretin®, retinoids approved by the FDA for the treatment of cancer.

He is the author or inventor on more than 120 publications and patents. Dr. Heyman serves on the Board of Trustees of the Salk Institute for Biological Studies, and is a Board member of Receptos Inc., Organovo Inc., and BIOCOM. He is also a member of the Therapeutic Advisory Board for aTyr Pharma and serves on the Executive Committee of the UCSD Moores Cancer Center.

He was an NIH postdoctoral fellow and staff scientist at the Salk Institute, working with Dr. Ronald Evans. Dr. Heyman received a Ph.D. in pharmacology from the University of Minnesota and a BS in chemistry from the University of Connecticut.


Faculty SpeakersJon Hawkinson

Jon Hawkinson, Ph.D.

Associate Program Director
Department of Medicinal Chemistry
Institute for Therapeutics 
Discovery and Development

"Drug Discovery Capabilities in the ITDD"

PubMed

 

Philip PortoghesePhilip Portoghese, Ph.D.

Distinguished Professor
Department of Medicinal Chemistry

"Mu opioid receptor heteromers are targets for treatment of inflammatory and neuropathic pain"

PubMed

 

Fang LiFang Li, Ph.D.

Associate Professor
Department of Pharmacology

"Animal origins and cross-species transmissions of SARS and MERS coronaviruses"

PubMed

 

Li-Na WeiLi-Na Wei, Ph.D.

Professor
Department of Pharmacology
Distinguished McKnight University Professor

"Receptor Interacting Protein 140 (RIP140) in diseases - A wild card to exploit"

PubMed

Jon Hawkinson, Ph.D.

Jon Hawkinson, Ph.D.

Philip Portoghese, Ph.D.

Philip Portoghese, Ph.D.

Fang Li, Ph.D.

Fang Li, Ph.D.

Li-Na Wei, Ph.D.

Li-Na Wei, Ph.D.

 


Postdoctoral AssociatesWilliam Kaya Erbil

William Kaya Erbil, Ph.D.

Postdoctoral Associate, Nicholas Levinson Lab

"Probing Dynamic Transitions in the Activation Pathway of cyclin-Dependent Kinase 2 (CDK2) by Nuclear Magnetic Resonance (NMR)"

Emily RuffEmily Ruff, Ph.D.

Postdoctoral Associate, Nicholas Levinson Lab

"Development of Kinase Allostery FRET Assays for Mechanistic Studies and Drug Design"

Chi Xu, Ph.D.

Chi XuPostdoctoral Associate, Ping-Yee Law Lab

"Morphine promotes astrocyte-preferential differentiation of mouse hippocampal progenitor cells via PKCε-dependent ERK activation and TRBP phosphorylation"

Related Publication

 

William Kaya Erbil, Ph.D.

William Kaya Erbil, Ph.D.

Emily Ruff, Ph.D.

Emily Ruff, Ph.D.

Chi Xu, Ph.D.

Chi Xu, Ph.D.

 


Chris RichardsGraduate Students

Christopher Richards

3rd Year Graduate Student
Mentor: Reuben Harris, Ph.D.

"Genetic and computational approaches elucidate the binding interface between human APOBEC3F and HIV-1 Vif"

Amanda SalzwedelAmanda Salzwedel

3rd Year Graduate Student
Mentor: Masato Yamamoto, M.D., Ph.D.

"Use of Oncolytic Adenovirus Expressing IFN-α To Treat Pancreatic Cancer"

Related Publication

Christopher Richards

Christopher Richards

Amanda Salzwedel

Amanda Salzwedel